Trial reportMolecular imaging and biology2016
A Feasibility Study Showing [
Trial report in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Drug-tolerant persister cells in cancer: the cutting edges and future directions.Nature reviews. Clinical oncology · 2023Review
- Assessing the Potential of Small Peptides for Altering Expression Levels of the Iron-Regulatory GenesInternational journal of molecular sciences · 2023Article
- Cottonseed oil alleviates ischemic stroke injury by inhibiting ferroptosis.Brain and behavior · 2023Article
- Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.European journal of medicinal chemistry · 2023Article
- Article
- Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.The Journal of experimental medicine · 2022Article
- The Evaluation ofMolecular imaging and biology · 2021Article
- Manipulating the In Vivo Behaviour ofInternational journal of molecular sciences · 2020Article
- Quantitative and Qualitative Improvement of Low-Count [Molecular imaging and biology · 2020Article
- Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.JCI insight · 2018Article
- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.Molecular cancer research : MCR · 2017Article
- Noninvasive Measurement of mTORC1 Signaling withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Development of aACS omega · 2017Article
- Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.Journal of Zhejiang University. Science. BReview
- Imaging Hepatocellular Carcinoma WithMolecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe management of advanced or recurrent prostate cancer is limited in part by the lack of effective imaging agents. Metabolic changes in prostate cancer have previously been exploited for imaging, culminating in the recent US FDA approval of [ PROCEDURES: Eight patients with castrate-resistant prostate cancer were enrolled in this single-center feasibility study. All patients had evidence of metastatic disease by standard of care imaging [X-ray computed tomography (CT), bone scan, or magnetic resonance imaging (MRI)] prior to PET with [
resultsAt 1- and 2-h imaging times post injection, there were no detectable lesions with [
conclusionsOur preliminary results support that PET with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.